Skip to main content
Premium Trial:

Request an Annual Quote

CellMax Life Launches With $14M in Funding, Early Colorectal Cancer Detection Test

NEW YORK (GenomeWeb) – Blood-based cancer testing firm CellMax Life officially launched today having raised $9 million in series A-1 venture financing, which — combined with earlier investments — brings its total funds raised to date to $14 million.

The $9 million funding round was led by Silicon Valley venture capital firm Artiman, as well as several Taiwanese venture investors including Acer Founder and Chairman Stan Shih, CellMax said.

The company plans to use the money to bring to market a variety of tests based on the detection of germline cancer risk mutations, circulating tumor cells, circulating tumor DNA, and epigenetic markers, with the goal of moving cancer care away from a focus on "intractable late-stages" toward detection and effective treatment at earlier stages.

The firm also announced the first of these tests today, a multi-biomarker assay for the early detection of colorectal cancer called CellMax CRC-Protect.

"Early detection is the best defense against this asymptomatic disease — when treatment costs are low and survival rates are high," said Co-founder and CEO Atul Sharan.

The company is currently marketing CRC-Protect in Taiwan, but eventually plans to expand to the US.

The Scan

Time to Act

A new report urges the UK to consider regulations to protect against the misuse of genomic technologies, according to the Guardian.

Fulgent Seeking Defamation Suit

Fulgent Genetics says it plans to sue Los Angeles County Sheriff Alex Villanueva for defamation, the Los Angeles Times reports.

Speeding Gene-Edited Crops

Reuters reports that China's new trial rules will make it easier to grow gene-edited crops there.

Nucleic Acids Research Papers on Viral Recombination, Pan-Cancer Mutations, SARS-CoV-2 Variability

In Nucleic Acids Research this week: updated pipeline to detect viral recombination, mutational patterns in tumor samples, and more.